In the randomized TOAD trial, delayed compared with immediate ADT in prostate cancer patients with PSA-only relapse after definitive treatment, or de-novo non-curable disease, was associated with fewer early adverse hormone-treatment-related symptoms, and did not affect overall functioning or quality of life [5]. Here, KLK3 is linked to prostate cancer.